» Articles » PMID: 8484829

Prognostic Significance of Progression of Coronary Atherosclerosis

Overview
Journal Circulation
Date 1993 Apr 1
PMID 8484829
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Angiographic progression of coronary atherosclerosis is frequently observed in clinical practice and is used as an end point in clinical trials; however, its prognostic significance is unclear.

Methods And Results: Progression defined as an increase in diameter stenosis by > or = 15% of at least one coronary lesion was seen in 141 (42%) of 335 patients who underwent repeat coronary arteriography after a 2-year interval as part of clinical trial. Coronary lesions were measured quantitatively from comparable end-diastolic frames selected by a radiologist viewing each pair of films together. During a mean follow-up of 44 +/- 10 months after the second arteriogram, cardiac death occurred in 19 patients (5.7%), cardiac death or nonfatal infarction was seen in 40 cases (11.9%), and 90 patients (26.9%) underwent coronary revascularization. At least one end point event occurred in 112 of the 335 patients. Sixteen of the 19 cardiac deaths were in progressors, a relative risk of 7.3 (95% CI, 2.2-24.7; p < 0.001). The relative risk of cardiac death or nonfatal infarction for progressors was 2.3 (1.3-4.2, p = 0.009) and of any cardiac event was 1.7 (1.3-2.3, p < 0.001). A stepwise multivariable Cox regression model of time to event was used to assess the relative contribution of progression as a predictor of coronary events. Low ejection fraction (p = 0.001), progression (p = 0.001), and hypertension (p = 0.011) were retained as predictors of cardiac death. Angina and the number of diseased vessels were the strongest predictors of revascularization.

Conclusions: Coronary progression is a strong, independent predictor of future coronary events, particularly cardiac death, and its use as a surrogate end point in clinical trials is justified.

Citing Articles

Cardiovascular disease among bariatric surgery candidates: coronary artery screening and the impact of metabolic syndrome.

Nie Y, Zong H, Li Z, Wang P, Zhang N, Zhou B Diabetol Metab Syndr. 2024; 16(1):180.

PMID: 39075584 PMC: 11285332. DOI: 10.1186/s13098-024-01425-6.


Association between non-culprit healed plaque and plaque progression in acute coronary syndrome patients: an optical coherence tomography study.

Yin W, Jing J, Zhang Y, Tian F, Zhang T, Zhou S J Geriatr Cardiol. 2021; 18(8):631-644.

PMID: 34527029 PMC: 8390931. DOI: 10.11909/j.issn.1671-5411.2021.08.001.


Aged Garlic Extract Reduces IL-6: A Double-Blind Placebo-Controlled Trial in Females with a Low Risk of Cardiovascular Disease.

Wlosinska M, Nilsson A, Hlebowicz J, Fakhro M, Malmsjo M, Lindstedt S Evid Based Complement Alternat Med. 2021; 2021:6636875.

PMID: 33868439 PMC: 8032523. DOI: 10.1155/2021/6636875.


Impact of daily glucose fluctuations on cardiovascular outcomes after percutaneous coronary intervention for patients with stable coronary artery disease undergoing lipid-lowering therapy.

Yamamoto H, Shinke T, Otake H, Kawamori H, Toba T, Kuroda M J Diabetes Investig. 2020; 12(6):1015-1024.

PMID: 33098191 PMC: 8169349. DOI: 10.1111/jdi.13448.


The effect of aged garlic extract on the atherosclerotic process - a randomized double-blind placebo-controlled trial.

Wlosinska M, Nilsson A, Hlebowicz J, Hauggaard A, Kjellin M, Fakhro M BMC Complement Med Ther. 2020; 20(1):132.

PMID: 32349742 PMC: 7191741. DOI: 10.1186/s12906-020-02932-5.